THE therapeutic effects of promin® (sodium p,p′-diaminodiphenyl-sulfone-N,N′-didextrose sulfonate) were studied in a group of common dermatoses. Senior members of the staff of the Department of Dermatology of the University of Pittsburgh School of Medicine participated in the study, and their independent observations were used as a basis for this report.
A total of 81 patients were treated with the drug for periods ranging from two weeks to twenty-seven months. The patients were arbitrarily divided into two groups. The first group consisted of 33 patients (table 1), whose disease was primarily of the chronic type, which had failed to respond to previous therapy. In the second group there were 48 patients (table 2) whose diseases were the more acute forms of dermatoses. Promin® was administered orally against all diseases except scleroderma, against which intravenous therapy was used. The oral administration consisted of a daily dosage of 0.8